Seattle based startup Cardiac Dimensions raises $17.5M for heart-valve repair device
| < 1 minute read
Cardiac Dimensions, a Kirkland, Wash.-based leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, closed a $17.5m Series C financing.
The financing will be used to accelerate commercial sales of Cardiac Dimensions’ Carillon Mitral Contour System in Europe and allow for expansion into other geographies such as Australia. Earlier this month, Australia’s Therapeutic Goods Administration approved the Carillon System for commercial use in FMR patients with mild to severe mitral regurgitation.
The Carillon System, CE-marked (0344), has been implanted in over 1,200 patients in the U.S., Europe, Australia, Turkey, and the Middle East. The Carillon System is currently being studied in The CARILLON Trial pivotal trial and limited to investigational use in the United States.
Suprotik Sinha is the Content Writer with Synkrama Technologies. He writes about technologies and startups in the global enterprise space. An animal lover, Suprotik, is a postgraduate from Symbiosis Institute of Mass Communication (SIMC) Pune. He carries 6+ years of experience in Content Writing, and he also worked in mainstream broadcast media, where he worked as a Journalist with Ibn7 ( now known as News18 India) and Zee Media in Mumbai.
About the author
Suprotik Sinha is the Content Writer with Synkrama Technologies. He writes about technologies and startups in the global enterprise space. An animal lover, Suprotik, is a postgraduate from Symbiosis Institute of Mass Communication (SIMC) Pune. He carries 6+ years of experience in Content Writing, and he also worked in mainstream broadcast media, where he worked as a Journalist with Ibn7 ( now known as News18 India) and Zee Media in Mumbai.
